68Ga-NOTA-RM26靶向胃泌素释放肽受体的PET/CT在胶质瘤评估及多区域活检联合中的应用
本研究纳入35例疑似胶质瘤患者,术前2周内行68Ga-NOTA-RM26 PET/CT,共评估32个胶质瘤病灶。68Ga-RM26 PET/CT对全部胶质瘤类型的诊断率为74.4%(27/32),对高级别胶质瘤的诊断率为95.8%(23/24);高级别胶质瘤的SUVmax、SUVmean及靶/本底比值均显著高于低级别胶质瘤(P<0.001)。作者认为68Ga-RM26可无创诊断高级别胶质瘤,并可能有助于指导胶质瘤多点活检。
要点
- 68Ga-RM26 PET/CT对高级别胶质瘤诊断率为95.8%(23/24),对全部胶质瘤类型为74.4%(27/32)。
- 高级别胶质瘤的SUVmax、SUVmean及T/B比值显著高于低级别胶质瘤(P<0.001)。
- 68Ga-RM26 PET/CT参数与胶质瘤免疫组化染色评分高度相关(P<0.001),并经多点活检验证。
核心结论
- 68Ga-RM26可无创诊断高级别胶质瘤,并可能是术前预测胶质瘤分级的有前景的PET示踪剂。
- 本先导研究表明68Ga-RM26摄取与胶质瘤WHO分级相关,术前68Ga-RM26 PET/CT可能有助于指导胶质瘤多点活检。
研究设计与样本
- 经机构审查委员会批准并签署知情同意后,共纳入35例疑似胶质瘤病灶的患者。
- 所有患者均在手术前2周内接受68Ga-RM26 PET/CT扫描。
主要发现
- 共32个胶质瘤病灶,包括8个II级、6个III级和18个IV级胶质瘤。
- 68Ga-RM26 PET/CT诊断了74.4%(27/32)的全部胶质瘤类型病灶,几乎全部高级别胶质瘤均成功诊断(23/24,95.8%)。
- 9个阴性胶质瘤病灶中有8个为低级别胶质瘤(II级)。
- 高级别胶质瘤的SUVmax、SUVmean和病灶/本底比值(T/B比值)显著高于低级别胶质瘤(P<0.001)。
- 胶质瘤免疫组化染色评分与68Ga-RM26 PET/CT参数(SUVmax、SUVmean和T/B比值)高度相关(P<0.001),并经68Ga-RM26 PET/CT引导的胶质瘤病灶多点取样免疫组化染色验证。
关键数值与推荐
- 68Ga-RM26 PET/CT对全部胶质瘤类型的诊断率为74.4%(27/32)。
- 68Ga-RM26 PET/CT对高级别胶质瘤的诊断率为95.8%(23/24)。
- 高级别胶质瘤与低级别胶质瘤的SUVmax、SUVmean和T/B比值差异有统计学意义(P<0.001)。
- 胶质瘤免疫组化染色评分与SUVmax、SUVmean和T/B比值高度相关(P<0.001)。
临床怎么用
- 作者认为术前68Ga-RM26 PET/CT可能有助于指导胶质瘤多点活检。
- 作者认为68Ga-RM26可能是术前预测胶质瘤分级的有前景的PET示踪剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the value of 68 Ga-NOTA-RM26 ( 68 Ga-RM26), a gastrin-releasing peptide receptor-targeting antagonist labeled with the radionuclide 68 Ga, in the diagnosis of high-grade gliomas and in combination with multiregional biopsies using PET/CT. PATIENTS AND METHODS: After institutional review board approval and informed consent, a total of 35 patients with suspected glioma lesions were enrolled in this study. All patients underwent 68 Ga-RM26 PET/CT scans within 2 weeks before surgery. RESULTS: There were 8 grade II gliomas, 6 grade III gliomas, and 18 grade IV gliomas in a total of 32 glioma lesions. 68 Ga-RM26 PET/CT diagnosed 74.4% of lesions (27/32) of all glioma tumor types, and almost all high-grade gliomas were successfully diagnosed (23/24, 95.8%). Among the 9 negative glioma lesions, there were 8 low-grade gliomas (grade II). There was a significantly higher SUV max , SUV mean , and the lesion-to-background ratio (T/B ratio) in high-grade gliomas compared with low-grade gliomas ( P < 0.001). In addition, there was a high correlation between the immunohistochemical staining score of gliomas and parameters (SUV max , SUV mean , and T/B ratio) on 68 Ga-RM26 PET/CT ( P < 0.001), and verified by immunohistochemical staining on multiple-point samples of glioma lesions guided by 68 Ga-RM26 PET/CT. CONCLUSIONS: 68 Ga-RM26 could noninvasively diagnose high-grade gliomas and be a promising PET tracer for predicting glioma grading before surgery. This pilot study indicated that the uptake of 68 Ga-RM26 correlates with WHO grade in glioma, and preoperative 68 Ga-RM26 PET/CT may be helpful to guide multiple-point biopsy of gliomas.
引用
- Wang R, Li Y, Li Z, et al. Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies. Clin Nucl Med. 2025. PMID: 39806560. doi:10.1097/RLU.0000000000005651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。